It was observed in hepatocellular carcinoma that IL-17-driven AKT signaling activation resulted in IL-6 production, which in turn activated JAK2–STAT3 signaling and subsequently upregulated its downstream targets, IL-8, MMP2, and VEGF [43]. The gene discussed is JAK2; the disease is hepatocellular carcinoma.